A patent drug is a medication protected by one or more patents, giving its manufacturer the exclusive right to produce and sell it for a limited period. You’ll also hear these called “brand-name drugs” or “patented drugs.” The patent prevents other companies from making, using, or selling the same drug, which is why brand-name medications cost significantly more than their generic equivalents.
How Drug Patents Work
A pharmaceutical patent functions like any other patent: it grants the inventor a temporary monopoly in exchange for publicly disclosing the invention. To qualify, a drug must meet three basic criteria. It has to be novel (no one has made it before), non-obvious (a skilled chemist wouldn’t consider it a trivial next step), and useful (it has a real medical application).
Drug manufacturers can patent several different aspects of a medication. The active ingredient itself is the most important, but patents can also cover the specific formulation, the composition of the pill or injection, and particular methods of use (treating a specific condition, for example). Each of these patents may have different filing dates and expiration timelines, which means a single brand-name drug can be shielded by a web of overlapping patents.
The FDA maintains a public database called the Orange Book that lists every approved brand-name and generic drug alongside the patents covering them and their expiration dates. Generic drug makers use this database to identify which patents stand between them and bringing a cheaper version to market.
How Long Patent Protection Lasts
A U.S. drug patent lasts 20 years from the date the application is filed. That sounds like a long time, but the clock starts ticking well before the drug reaches pharmacy shelves. A manufacturer typically files for a patent early in the development process, then spends years running clinical trials and waiting for FDA approval. By the time patients can actually buy the drug, a significant chunk of those 20 years has already passed.
To compensate for this, Congress passed a law in 1984 that allows manufacturers to reclaim some of that lost time. The extension is calculated based on two phases: the testing phase (from the start of clinical trials to the submission of the approval application) and the approval phase (the time the FDA spends reviewing it). Half the testing phase plus the full approval phase equals the eligible extension period, though there are caps on how much time can be added back.
Internationally, the picture is similar. The World Trade Organization’s TRIPS agreement requires all member nations to provide a minimum patent term of 20 years from the filing date. This created a uniform global standard, meaning pharmaceutical patents work on roughly the same timeline whether a drug is sold in the U.S., Europe, or Japan.
Why Drug Patents Exist
Developing a new drug is expensive and risky. A 2024 analysis published in JAMA Network Open estimated that the average cost of bringing a single new drug to market is roughly $173 million. When you factor in the cost of all the failed candidates that never made it through trials, that figure jumps to about $516 million. Other estimates, depending on the therapeutic area and modeling assumptions, range from $314 million to over $4 billion.
Patents exist to make that gamble worthwhile. Without a period of exclusivity, a competitor could simply copy a newly approved drug, skip the years of research, and sell it at a fraction of the price. The original developer would never recoup its investment, and the financial incentive to discover new treatments would collapse. The patent system is essentially a trade-off: the public grants a temporary monopoly, and in return, it gets new medicines that might not otherwise exist.
What Happens When a Patent Expires
Once a drug’s patents expire, other manufacturers can apply to produce generic versions. Generic drugs contain the same active ingredient, in the same dose and form, as the original. They don’t need to repeat full clinical trials. Instead, they only need to demonstrate that their version is absorbed by the body in the same way as the brand-name product.
The price effects are dramatic. A systematic review of 12 studies found that generic drug prices typically fall to between 7% and 66% of the brand-name price within one to five years after patent expiry. In one U.S. study, generics dropped to about 55% of the original price within 12 months. In the UK, prices fell even more steeply, dropping to roughly 4% of the original price within four years. The more generic competitors that enter the market, the lower prices tend to go. One analysis found that each additional generic manufacturer drove prices down by about 13% on average.
How Companies Extend Their Monopoly
Pharmaceutical companies sometimes use a strategy known as “evergreening” to push back the date when generics can enter. Rather than inventing an entirely new drug, they file additional patents on modifications to the existing one. These secondary patents might cover a new formulation (switching from a capsule to a tablet), a different dosage, an alternative delivery method (switching from an intravenous infusion to a subcutaneous injection), or even new packaging.
A well-known example involves the breast cancer drug trastuzumab. Its manufacturer received approval for a new subcutaneous injection form in 2013, just months before the patent on the original intravenous version expired in 2014. The new patent on the injection form effectively extended the period of market exclusivity, delaying the uptake of cheaper alternatives.
These strategies are legal, and the new versions sometimes offer genuine benefits to patients, like more convenient dosing. But critics argue that many of these modifications are minor and exist primarily to block generic competition and keep prices high. It’s one of the most contentious issues in pharmaceutical policy, sitting at the intersection of innovation incentives and drug affordability.
Patent Protection vs. FDA Exclusivity
Patents aren’t the only barrier to generic competition. The FDA also grants periods of “marketing exclusivity” that are separate from patent rights. For instance, a completely new active ingredient gets five years of exclusivity from its approval date, during which the FDA won’t even accept a generic application. Drugs approved for new uses or in new forms can receive three years. Orphan drugs (those treating rare diseases) receive seven years.
The key difference: patents are granted by the Patent and Trademark Office based on the invention itself, while exclusivity is granted by the FDA as a reward for completing the clinical work needed for approval. The two protections can overlap, and whichever one lasts longer is the one that effectively keeps generics off the market. In practice, drug companies rely on both systems working together to maximize the window during which they’re the only seller.